Please provide your email address to receive an email when new articles are posted on . The U.S. Food and Drug Administration approved Bausch + Lomb’s new drug application for bromfenac ophthalmic ...

The FDA has granted Bausch + Lomb approval for PROLENSA, its anti-inflammatory prescription eye drop for patients that have undergone cataract surgery. The bromfenac ophthalmic solution, which will be ...

PROLENSA (bromfenac) ophthalmic solution The FDA has approved Bausch & Lomb's New Drug Application for Prolensa ophthalmic solution, which treats post-operative inflammation and reduces ocular pain in ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted tentative approval to Perrigo Company plc for its generic ...

New Once-Daily NSAID Indicated for Treatment of Postoperative Inflammation and Reduction of Ocular Pain Following Cataract Surgery PROLENSA provides powerful and rapid resolution of inflammation and ...

Bromfenac ophthalmic solution is a nonsteroidal anti-inflammatory drug indicated for postoperative inflammation in patients who have undergone cataract surgery. Alembic is releasing bromfenac ...

ISTA Pharmaceuticals says it snagged the late-stage data it needs to win an approval for Prolensa, which relies on a low concentration of bromfenac to treat pain and inflammation caused by cataract ...

Company announced that the United States Patent and Trademark Office has issued Patent No. 8,129,431 with claims covering PROLENSA(TM) (bromfenac ophthalmic solution), ISTA's once-daily topical ...

Today the Food and Drug Administration (FDA) approved a new formulation of a once-daily nonsteroidal anti-inflammatory drug (NSAID) for the treatment of postoperative pain and inflammation in patients ...